STAT+: Pharmalittle: We’re reading about an FDA meeting on MDMA, a new obesity pill, and more
Top of the morning to you, and a fine one it is. There is nothing…
Category: Pharma
STAT+: Tracking the FDA advisory panel on MDMA therapy for PTSD
Good morning, and welcome to STAT’s live blog of the Food and Drug Administration’s scientific…
STAT+: Leading CRO to pay record fine for badly neglecting hundreds of beagles in breeding facility
A leading contract research organization has agreed to pay $35 million — including the largest-ever…
STAT+: Pharmalittle: We’re reading about Zantac lawsuits, worries over MDMA for PTSD, and more
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
Can AstraZeneca make good on its promise?
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: ASCO Daily Recap: AstraZeneca’s hat trick, a GSK turnaround, and palliative care as telehealth
You’re reading the web edition of ASCO in 30 Seconds, STAT’s guide to the American…
STAT+: AstraZeneca’s Tagrisso greatly slows cancer for some people with stage 3 lung cancer
In patients with stage 3 lung cancer where a particular genetic mutation is present in…
STAT+: With new results at ASCO, Enhertu once again rewrites rules of breast cancer treatment
CHICAGO — The cancer drug Enhertu stalled the growth of tumors by more than a…
STAT+: ASCO 2024: Data put a new shine on GSK blood cancer drug that was pulled from market
LONDON — The resurrection of a GSK blood cancer drug — which the company withdrew…
STAT+: ASCO Daily Recap: Safety data for Novartis myelofibrosis candidate, survival data for Pfizer drug
You’re reading the web edition of ASCO in 30 Seconds, STAT’s guide to the American…
.jpg)
STAT+: At ASCO, pharma leaders explain how ‘smart bomb’ drugs became useful against more cancers
CHICAGO — The ways clinicians can treat cancers effectively are expanding, partly because technologies today…
.jpg)
STAT+: ASCO 2024: FDA oncology head wants clinical trials to range beyond China alone
CHICAGO — The Food and Drug Administration’s top oncologist reiterated that the agency doesn’t want drugmakers…
STAT+: Pharmalittle: We’re reading about docs paid for endorsements, Novartis suing Maryland, and lots more
And so, another working week will soon draw to a close. Not a moment too…
The surprising outperformance of a new drug against existing competitors, and other biotech updates
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Novartis sues Maryland over the role of contract pharmacies in a U.S. drug discount program
Novartis has filed a lawsuit seeking to block a Maryland law that requires the company…
STAT+: Many docs who tweeted product endorsements also took money from manufacturers, analysis shows
Most physicians who endorsed a prescription drug or medical device on X — formerly known…
Biohaven’s autoimmune drug disappoints, and other biotech news updates from the week
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Pharmalittle: We’re reading about a deal for a Moderna bird flu shot, NIH trial shortcomings, and more
Rise and shine, everyone, another busy day is on the way. We can tell because…
STAT+: Pharmalittle: We’re reading about a Merck deal, weight loss drugs, and lots more
Hello, everyone, and how are you today? We are doing just fine, thank you, especially…
Wegovy linked to lower risk of alcohol use disorder in real-world study
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Reports: Looking to expand its pipeline, Merck to buy eye-disease startup EyeBio
LONDON — Merck is buying ophthalmology-focused startup EyeBio in a deal worth up to $3…
STAT+: Pharmalittle: We’re reading about the Cencora data breach, a failed pandemic treaty, and more
Good morning, everyone, and welcome to another working week. We hope the weekend respite —…
Biotech’s most interesting fundraisings from the last week
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Pharmalittle: We’re watching more positive data for Ozempic, a Lilly factory expansion, and more
It’s an honor to fill in for Ed Silverman this morning. There is only one…
More tumult at BIO amid the company’s fourth CEO in four years
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: After MDMA therapy, she considered suicide. The trial data tell a different story
The MDMA study was her last hope. She had read headlines celebrating a 83% response…
In light of H5N1 outbreak, U.S. in talks with mRNA vaccine makers on bird flu
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Pharmalittle: We’re watching a Cytokinetics deal with Royalty Pharma, Cue Health shutting down, and more
Top of the morning to you. I’m filling in for Ed Silverman this morning, which…
STAT+: Biotechs turn to gene silencing for obesity drugs that can last longer than Wegovy
Enticed by the immense market opened by GLP-1 weight loss drugs Wegovy and Zepbound, a…
Maryland takes first steps to cap drug costs
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Pharmalittle: We’re watching a ban compounded versions of GLP-1s, a Biogen acquisition, and more
Good morning from San Diego. This is Jonathan Wosen, West Coast biotech and life sciences…
STAT+: Pharmalittle: We’re watching BIO layoffs, AstraZeneca plans to double revenue, and more
Good morning from the Pharmalittle campus, where I’m filling in for Ed. Normally, I’m the…
Lilly doubles down on radiopharma
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Pharmalittle: We’re reading about Sanders’ pharma pressure campaign, AstraZeneca’s new ADC factory, and more
Good morning from STAT reporter Andrew Joseph, filling in here for Mr. Pharmalot. We’ve recently…
STAT+: Pharmalittle: We’re reading about an Amgen drug for lung cancer, a Novo plant fire, and more
And so, another working week will soon draw to a close. Not a moment too…
AstraZeneca antibody reduced Covid-19 risk in immunocompromised
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Analysis of pharmaceutical R&D ranks Novo Nordisk and Johnson & Johnson above their peers
When it comes to bringing an experimental drug to market and selling it, Novo Nordisk,…
STAT+: Pharmalittle: We’re reading about a Roche obesity drug, an experimental Lilly insulin, and more
Top of the morning to you, and a fine one it is, despite the gray…
Blackstone wants in on red-hot immunology market
The need-to-know this morning Biogen and Ionis Pharmaceuticals are ending their development of an experimental drug for ALS based on…
STAT+: Obesity drug from Roche succeeds in early test, sending company shares up
LONDON — Roche on Thursday said its recently acquired experimental obesity medication helped people lose…
STAT+: Getting abortion pills through the mail is safe, quick, and effective, study finds
Amid a national furor over access to abortion, a new study found that dispensing abortion…
Leqembi gets closer to being offered as an injection
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Pharmalittle: We’re reading about fake studies, AbbVie investing in psychedelics, and more
Good morning, everyone, and welcome to the middle of the week. Congratulations on making it…
STAT+: Lawmaker accuses Amgen of placing profits above patients with dosing for a cancer drug
A U.S. lawmaker is accusing Amgen of “putting profits before patients” over its decision to…
STAT+: Novo to test Wegovy and other obesity drugs against alcohol-related liver disease
Novo Nordisk will test whether its GLP-1 drugs can help people with alcohol-associated liver disease,…
Is Novavax a new meme stock?
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Pharmalittle: We’re reading about Pfizer’s DTC platform, Sandoz’s feud with a U.K. trade group, and more
Rise and shine, everyone, another busy day is on the way. We can tell thanks…
STAT+: Sandoz leaves U.K. trade group over dispute about promoting a biosimilar for multiple sclerosis
In an unusual move, Sandoz is no longer cooperating with a U.K. industry trade group…
STAT+: Pharmalittle: We’re reading about FDA dithering on pharma patents, WHO pandemic talks, and more
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
We now know Tome’s gene editing target
Want to stay on top of the science and politics driving biotech today? Sign up to get…